IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kozikowski, A. et al.

Examiner: Chang, C. C.

Application No.: 10/576,620

Art Unit: 1625

Filed: April 21, 2006

Atty. Docket No.: GUX-010.01

Title: Dopamine-, Norepinephrine-, and Serotonin-

Transporter-Selective Heterocyclic Compounds

and Their Therapeutic Applications

Mail Stop: Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the U.S. patents listed on the accompanying Form PTO/SB/08, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of references BA and BB are attached hereto.

INFORMATION DISCLOSURE STATEMENT APPL. NO.: 10/576,620 DOCKET NO.: GUX-010.01

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

M	(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
	(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
		the requisite Statement is below, OR
		the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or
	(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND
		the requisite Statement is below, AND
		the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO/SB/08, and other information contained herein, be made of record in this application.

INFORMATION DISCLOSURE STATEMENT APPL. NO.: 10/576,620 DOCKET NO.: GUX-010.01

STATEMENT

that [c	equired under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state heck the appropriate space only if either (2) or (3) is checked on the previous e Statement is required!:
1.	Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
2.	No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
	Respectfully submitted,

Date: September 10, 2009

Reg. No. 44,719

Tel. No. (617) 832-1000

Fax No. (617) 832-7000

/Dana M. Gordon/
Dana M. Gordon, Ph.D.
Attorney for Applicants
Foley Hoag LLP

155 Seaport Boulevard